Abstract:
Cytokeratin (CK)+/CD45−/DAPI+ cells in the blood of cancer patients have been considered by most as circulating tumor cells (CTCs). Different methods of isolating CTCs results in a wide range of numbers and subgroups of CTCs from same patient. As a result, the clinical significance of the number of CTCs becomes cloudy. Provided herein is methodology to categorize CTCs into morphologically distinct subpopulations, and to use one of the subpopulations in methods for predicting overall survival of a patient having cancer.
Abstract:
A new sensitive cell biomarker of solid tumors and viral infection is identified in blood. This biomarker can be used to determine presence of carcinomas, sarcomas, and viruses, rapid determination of treatment response, early detection of cancer, early detection of cancer recurrence, and may be used to determine therapy.
Abstract:
A new sensitive cell biomarker of solid tumors and viral infection is identified in blood. This biomarker can be used to determine presence of carcinomas, sarcomas, and viruses, rapid determination of treatment response, early detection of cancer, early detection of cancer recurrence, and may be used to determine therapy.
Abstract:
Methods of using detection of PD-L1 expression by circulating cancer cells in the screening, monitoring, treatment and diagnosis of cancer in subjects are disclosed. The methods are based on assaying one or more of circulating tumor cells (CTCs), epithelial to mesenchymal transition CTCs (EMTCTCs), cancer associated macrophage-like cells (CAMLs), and cancer associated vascular endothelial cells (CAVEs) isolated from a subject having cancer for PD-L1 expression.
Abstract:
Means for predicting treatment response in a subject having cancer are disclosed, where the predictions are based comparing the number and size of circulating cancer associated macrophage-like cells (CMLS) and circulating tumor cells (CTCs) found in biological samples at baseline and after induction of therapy, such as blood, from the subject.
Abstract:
Means for predicting overall survival (OS) and progression free survival (PFS) of subjects having cancer are disclosed, where the predictions are based on the number arid size of circulating cancer associated macrophage-like cells (CAMLs) found in a biological sample, such as blood, from the subject.
Abstract:
A microfilter comprising a polymer layer formed from photo-definable dry film, and a plurality of apertures each extending through the polymer layer. A microfilter comprising two or more polymer layers formed from photo-definable dry film, and a plurality of apertures or open areas each extending through the polymer layer. Methods of forming apertures in one or more layers of photo-definable dry film are also disclosed. Filter holder designs and methods appropriate to hold microfilters to collect the rare cells and to perform of assays in the filter holder are provided. Microfiltration chip designs and methods appropriate to collect the rare cells and to perform assays in the microfluidic chips are provided. The invention also describes the use of the microfilter, filter holder and microfilter chips to collect rare cells from body fluids and perform assays, and these rare cells can be used for medical and biological research applications.
Abstract:
Means for predicting overall survival (OS) and progression free survival (PFS) of subjects having cancer are disclosed, where the predictions are based on the number of CCR5 pools in circulating cells, such as circulating cancer associated macrophage-like cells (CAMLs) and circulating tumor cells (CTCs) found in a biological sample, such as blood, from the subject. CCR5 expression can also be used for companion or complementary diagnostics.
Abstract:
Circulating tumor cells (CTCs) are associated with metastasis of malignant solid tumors in a patient. Presented here is evidence that CTCs exhibit cell cycle phase variability and that there is a strong correlation between the number of CTCs in a mitotic cell cycle phase and the prospects for long term survival of the subject from which the cells were obtained. Also presented herein are methods of determining the mitotic cell cycle phase of CTCs from a patient having cancer and using the information in grading malignant solid tumors and predicting the likelihood of survival of the patient.
Abstract:
Means for monitoring treatment response and disease progression in subjects are disclosed, where the predictions are based on the change of number and/or size of circulating cancer associated macrophage-like cells (CAMLs) found in a biological ample, such as blood, from the subject.